WallStSmart

Baird Medical Investment Holdings Limited (BDMD)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 325162% more annual revenue ($79.67B vs $24.49M). LLY leads profitability with a 33.5% profit margin vs -64.9%. LLY earns a higher WallStSmart Score of 76/100 (B+).

BDMD

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 4.0
Piotroski: 1/9Altman Z: -0.02

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDMD2 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
24.6%8/10

Revenue surging 24.6% year-over-year

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$994.92B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
33.5%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
54.2%10/10

Strong operational efficiency at 54.2%

Revenue GrowthGrowth
47.7%10/10

Revenue surging 47.7% year-over-year

EPS GrowthGrowth
26.2%8/10

Earnings expanding 26.2% YoY

Areas to Watch

BDMD4 concerns · Avg: 2.5/10
Market CapQuality
$35.18M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-48.1%2/10

ROE of -48.1% — below average capital efficiency

EPS GrowthGrowth
-0.3%2/10

Earnings declined 0.3%

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.623/10

Elevated debt levels

Price/BookValuation
29.4x2/10

Trading at 29.4x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BDMD

The strongest argument for BDMD centers on Price/Book, Revenue Growth. Revenue growth of 24.6% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.

Bear Case : BDMD

The primary concerns for BDMD are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

LLY carries more volatility with a beta of 0.50 — expect wider price swings.

LLY is growing revenue faster at 47.7% — sustainability is the question.

LLY generates stronger free cash flow (7.8B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (76/100 vs 36/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baird Medical Investment Holdings Limited

HEALTHCARE · MEDICAL DEVICES · USA

Baird Medical Investment Holdings Limited, along with its subsidiaries manufactures microwave ablation and other medical devices for minimally invasive tumor treatment. The company is headquartered in Guangzhou, China.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?